uniQure has presented new results from its phase 1/2 study of its gene therapy for Huntington’s disease that it said were positive, although investors are far from convinced by the data.

A survey conducted in Canada examined the prevalence of perceived genetic discrimination against patients with Huntington disease. The respondents reported discrimination not only by insurance or ...

Shares in gene therapy developer uniQure have risen more than 75% after the company reported that Huntington’s disease candidate AMT-130 slowed down the progression of the disorder over two years.

A 14-year study tracking NfL levels in people with the HD gene shows this tiny protein can signal disease progression many ...

According to the University of California San Francisco, Huntington’s disease affects one in every 10,000 to 20,000 people in ...

ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in mice with Huntington’s disease by more than 80%. The therapy had no ...

“As someone who has devoted my career to Huntington’s disease (HD), I am tremendously excited about the advancements we've made in developing a gene therapy that targets the somatic ...

The Missouri Chapter of the Huntington's Disease Society of America will host a Team Hope walk Saturday, April 12, at Jackson ...

Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease to members of the Huntington's Disease Youth Organization, at the annual HYDO ...